Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable Hormone Sensitive and HER2-Negative Primary Breast Cancer

  • STATUS
    Recruiting
  • End date
    Jun 1, 2022
  • participants needed
    200
  • sponsor
    Kyoto Breast Cancer Research Network
Updated on 27 June 2021
cancer
breast cancer
endocrine therapy
neutrophil count
hormone therapy
HER2
her-2
invasive breast cancer

Summary

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone measured by PEPI and EndoPredict EPclin Score in women with operable HR+, HER2 negative breast cancer . The Clinical Response Rate, drop in Ki67 index 2.7% and Breast conserving rate will be compared between two arms.

Details
Condition Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
Treatment Palbociclib, Endocrine Therapy
Clinical Study IdentifierNCT03969121
SponsorKyoto Breast Cancer Research Network
Last Modified on27 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note